DRUG
Dydrogesterone
progestin primed ovarian stimulation
DYG Versus Cetrorelix in Oocyte Donation
Status
Completed
Phase
Not applicable
Enrollment
202
Locations
0
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
Prospective controlled study to assess the reproductive outcomes of OD recipients in which the donors were subjected to the DYG protocol (20mg/day) compared with those subjected to the short protocol with cetrorelix (0.25 mg/day) from Day 7 or since a leading follicle reached 14 mm. The OD cycles were triggered with triptoreline acetate and the trigger criterion was ≥3 follicles of diameter \>18mm.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Oct 13, 2022
Study start
Jan 1, 2017
Primary completion
Dec 31, 2021
Study completion
Dec 31, 2021
Results posted
Not reported
Registry updated
Oct 13, 2022
Outcomes
What the study measures.
Primary outcomes
Live Birth Rate per transfer
Time frame · 40 weeks after ET
Clinical pregnancy per transfer
Time frame · 12 weeks after ET
Miscarriage rate
Time frame · 12 weeks after ET
Secondary outcomes
Number of oocytes retrieved
Time frame · at time of oocyte retrieval
Number of mature oocytes
Time frame · 1 day after IVF
Number of fertilized oocytes
Time frame · 1 day after IVF
Number of blastocists
Time frame · 5-6 days after OPU
Eligibility
Who can take part.
- Minimum age
- 21 Years
- Maximum age
- 30 Years
- Sex
- FEMALE
- Healthy volunteers
- Not reported
Inclusion Criteria: * Oocyte donors between 21 and 30 years old, with regular menstrual cycles (24-35 d) and a body mass index (BMI) between 18 and 28 kg/m2 without any relevant personal or family history Exclusion Criteria: * AMH less than 3 ng/dL * A positive screening for sexually transmitted diseases
Study locations
0 registered sites.
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Cetrorelix.
NCT IDStudyPhase / statusEnrollmentUpdated
Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF/ICSI
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Oral GnRH Antagonist (Linzagolix) Versus Injectable GnRH Antagonist for Ovarian Stimulation in IVF/ICSI
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
NATural Ovarian Stimulation
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.